Projection systems enhance large-screen image viewing
Barco introduced two medical-grade reviewing and conferencing projection systems Sunday at the RSNA meeting, adding to its line of large-screen imaging displays.
Barco introduced two medical-grade reviewing and conferencing projection systems Sunday at the RSNA meeting, adding to its line of large-screen imaging displays.
DICOM Theater Lite, a lightweight portable system, provides 1400 x 1050-pixel Super XGA+ resolution, 2000:1 contrast, 2000-lumen light output, and silent operation. Fully compliant with DICOM quality standards for image accuracy, Theater Lite can be connected to PACS workstations seamlessly via the BarcoMed display controller.
DICOM Theater Pro, the company's premier medical projection system, can display images from several sources using a single projector. It features an MGP 15 projector, a dedicated BarcoMed display controller, MediCal Pro QA software, and Barco's I-Guard sensors. Because of its integrated smart dual lamp design and high-resolution Poly-SI LCT technology, Theater Pro projects images with a 4500-lumen brightness.
MediCal Pro QA works with commercially available sensors as well as the I-Guard to maintain conformity and consistency of single color, gray-scale, CRT, or liquid crystal displays. The I-Guard feature stabilizes the projection of continuous images and adds DICOM compatibility.
All DICOM Theater projection systems are suitable for use with PACS as well as other source images, including computer data, endoscopy, and ultrasound.
FDA Clears Virtually Helium-Free 1.5T MRI System from Siemens Healthineers
June 26th 2025Offering a cost- and resource-saving DryCool magnet technology, the Magnetom Flow.Ace MRI system reportedly requires 0.7 liters of liquid helium for cooling over the lifetime of the device in contrast to over 1,000 liters commonly utilized with conventional MRI platforms.
SNMMI: Botox May Facilitate Relief from Dry Mouth Side Effect of PSMA-Targeted Radiopharmaceuticals
June 25th 2025For patients being treated with radiopharmaceutical agents for metastatic prostate cancer, the combination of botulinum toxin and an anti-nausea patch led to a 30 percent reduction in PSMA uptake in the salivary glands, according to preliminary research findings presented at the SNMMI conference.
